Search clinical trials for: Amikacin (BAY41-6551)

Total 278 results

Bayer

Completed

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (ORACLE)

Chronic Myelogenous Leukemia

United States, France
Bayer

Completed

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
University of Florida

Terminated

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

Bacterial Pneumonia

United States, Spain, France, Germany
Bayer

Terminated

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

Carcinoma, Renal Cell
Bayer
Amgen

Completed

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Carcinoma, Renal Cell

United States, United Kingdom
Bayer

Completed

Hepatic Impairment Study

Liver Disease

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States
Bayer

Completed

BAY43-9006 - Phase II in Advanced Breast Cancer

Breast Cancer | Breast Neoplasms

Italy, Germany
Bayer

Completed

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Cancer

Canada
Bayer

Completed

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (STORM)

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Hong Kong, United States, Canada, Switzerland, Germany, Portugal, Taiwan, Japan, Russian Federation, Singapore, Austria, United Kingdom, Korea, Republic of, Australia, New Zealand, Mexico, Brazil, Italy and more
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Bayer

Completed

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Belgium, Israel, Italy, France, United States
Bayer

Terminated

Research Study for Patients With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
Bayer

Completed

Dose-Finding Trial of Polyethylene Glycol 3350 Laxative Plus Electrolytes for the Treatment of Constipation (Protocol P07515)

Constipation

Ireland
Bayer

Completed

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (SHARP)

Carcinoma, Hepatocellular

Belgium, Italy, Spain, Canada, Switzerland, Germany, Greece, Russian Federation, France, United States, United Kingdom, Chile, New Zealand, Australia, Romania, Bulgaria, Croatia, Israel, Peru, Poland, Mexico, Brazil, Argentina
MedImmune LLC

Completed

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma

United States, France, Spain, Canada, Turkey, Israel, Germany, Russian Federation, Czechia, Hungary, Poland
Bayer

Withdrawn

Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer (POWER-NEXT)

Carcinoma, Renal Cell
Bayer

Completed

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Carcinoma, Hepatocellular

Korea, Republic of, Japan
Medical University of Graz

Completed

Testing of Personal Protective Equipment (PPE) (PPE-Test)

Personal Protective Equipment | Heat Stress

Austria
Northwestern University

Completed

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Infection

United States
Seattle Children's Hospital
Cystic Fibrosis Foundation

Completed

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Cystic Fibrosis | Chronic Bronchitis

United States
M.D. Anderson Cancer Center
Bayer

Withdrawn

Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma
Bayer

Terminated

Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment (SORAGO-HCC)

Hepatocellular Carcinoma

Germany
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Bayer

Completed

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib (ROCURS)

Coronavirus Disease 2019 (COVID-19) | SARS-CoV-2 Infection | Malignant Solid Tumors

United States
Bayer

Completed

A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

Melanoma

France, United Kingdom
NantCell, Inc.

Completed

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Metastatic Pancreatic Cancer

United States
BeiGene

Completed

Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

Hepatocellular Carcinoma (HCC)

China, Italy, United States, Germany, Japan, Taiwan, Czechia, Spain, United Kingdom, France, Poland
Bayer

Completed

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors (RIFTOS MKI)

Thyroid Neoplasms

United States, Japan, Turkey, Russian Federation, India, Germany, France, Mexico, Philippines, Greece, Netherlands, Spain, Taiwan, Brazil, Egypt, Argentina, Algeria, Lebanon, Saudi Arabia
Bayer

Completed

Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements.

Constipation

United States
Bayer

Completed

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)

Carcinoma, Hepatocellular

Belgium, France, Spain, Hong Kong, United States, Canada, Germany, Greece, New Zealand, Russian Federation, Australia, Taiwan, Austria, United Kingdom, China, Israel, Korea, Republic of, Bulgaria, Brazil, Poland, Italy, Colombia, South... and more
Bayer

Completed

To Evaluate Clinical Outcome and Injection Compliance of Scilin (SEAS)

Diabetes Mellitus, Type 2

China
National Institute of Allergy and Infectious Diseases...

Completed

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

HIV Infections | Mycobacterium Avium-intracellulare Infection

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma

United States
Bayer
Amgen

Completed

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Melanoma | Cancer

United States
Bayer

Completed

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Russian Federation, France, United States, Germany, Poland, Ukraine, United Kingdom
NanoBio Corporation

Completed

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS) (SHaRCS)

Recurrent Herpes Labialis

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); GlaxoSmithKline; Merck Sharp & Dohme LLC; Nova...

Completed

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
National Institutes of Health Clinical Center (CC)
National Eye Institute (NEI); Othera Pharmaceuticals

Completed

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

Age-Related Macular Degeneration | Geographic Atrophy | AMD

United States
Bayer

Completed

HCC Patient Preferences in Japan

Hepatocellular Cancer

Japan
Bayer

Completed

GLucobay M OBservation Study for Efficacy and Safety in Treatment of Type-2 Diabetes Patients (GLOBE)

Type 2 Diabetes

India
Al-Azhar University

Active, not recruiting

the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy

Pharmacological Action of Drug

Egypt
Amgen

Completed

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Lymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
Bayer

Active, not recruiting

A Study to Learn More About How Acarbose and Metformin Work When Taken Together and How Safe They Are in Indian Patients Who Were Recently Diagnosed With Type 2 Diabetes (T2D) (START-AM)

Type 2 Diabetes Mellitus

India
Bayer

Completed

Bioequivalence Study for Acarbose / Metformin FDC

Diabetes Mellitus, Type II

Korea, Republic of
Bayer

Withdrawn

GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice (GLORY)

Diabetes Mellitus, Type 2
Bayer

Completed

Bioequivalence Study for Acarbose/Metformin FDC

Diabetes Mellitus, Type 2

China
NantCell, Inc.

Completed

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Metastatic Colorectal Cancer

United States, Italy, France, Russian Federation, Spain, Hungary, Poland, Singapore, Hong Kong, India
Bayer

Completed

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS) (ACUTE)

Acute Coronary Syndrome

Spain, China, Germany, Russian Federation
Bayer
Amgen

Completed

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States, Canada, Germany, France, United Kingdom, Australia, Netherlands

3

Subscribe